Clinical Trial Update: 3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

This clinical trial update indicates that the Phase 1 study of 3,3'-Diindolylmethane in patients with systemic lupus erythematosus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• 3,3'-Diindolylmethane (3,3'-Diindolylmethane)

Snippet

Sponsor: Northwell Health | Conditions: SLE | Phase 1 | Status: TERMINATED